Glanbia (OTCMKTS:GLAPY) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday, Zacks.com reports.

According to Zacks, “Glanbia Plc engages in the manufacture and distribution of dairy and nutritional food products. Its operating segments include Glanbia Performance Nutrition, Global Ingredients, Dairy Ireland and Joint Ventures and Associates. Glanbia Performance Nutrition segment comprises of performance nutrition products under the Optimum Nutrition, BSN, Isopure, Nutramino and ABB brands. Global Ingredients segment includes American-style cheddar cheese, micro-nutrient premixes and dairy and non-dairy nutritional solutions. Dairy Ireland segment consists of consumer products and agribusiness. Joint Ventures and Associates segment covers Glanbia Ingredients Ireland, Glanbia Cheese and Southwest Cheese. Glanbia Plc is headquartered in Kilkenny, Ireland. “

Separately, Jefferies Financial Group upgraded shares of Glanbia from a “hold” rating to a “buy” rating in a research report on Friday.

OTCMKTS:GLAPY traded up $4.25 during trading hours on Tuesday, reaching $61.45. The company had a trading volume of 302 shares, compared to its average volume of 3,105. The stock has a 50-day moving average of $63.18 and a two-hundred day moving average of $84.75. Glanbia has a one year low of $53.60 and a one year high of $107.19. The firm has a market capitalization of $3.64 billion, a PE ratio of 11.44, a PEG ratio of 1.64 and a beta of 0.23.

Glanbia Company Profile

Glanbia plc operates as a nutrition company worldwide. It operates through three segments: Glanbia Performance Nutrition, Glanbia Nutritionals, and Glanbia Ireland. The Glanbia Performance Nutrition segment manufactures and sells sports nutrition and lifestyle nutrition products in various formats, including powders, ready-to-eat bars and snacking foods, and ready-to-drink beverages through various channels, such as specialty retail, the Internet, and gyms, as well the food, drug, mass, and club channels.

See Also: What is a stock portfolio tracker?

Get a free copy of the Zacks research report on Glanbia (GLAPY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Glanbia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glanbia and related companies with MarketBeat.com's FREE daily email newsletter.